16,836 Shares in Moderna, Inc. $MRNA Acquired by Cynosure Group LLC

Cynosure Group LLC purchased a new stake in Moderna, Inc. (NASDAQ:MRNA) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 16,836 shares of the company’s stock, valued at approximately $496,000.

Other institutional investors have also recently bought and sold shares of the company. MUFG Securities EMEA plc bought a new position in Moderna in the second quarter valued at approximately $28,000. Flagship Harbor Advisors LLC bought a new stake in Moderna in the 4th quarter valued at $31,000. Ameriflex Group Inc. lifted its position in Moderna by 3,775.0% in the 3rd quarter. Ameriflex Group Inc. now owns 1,240 shares of the company’s stock valued at $32,000 after acquiring an additional 1,208 shares in the last quarter. Cromwell Holdings LLC lifted its position in Moderna by 39.7% in the 4th quarter. Cromwell Holdings LLC now owns 1,200 shares of the company’s stock valued at $35,000 after acquiring an additional 341 shares in the last quarter. Finally, EverSource Wealth Advisors LLC lifted its position in Moderna by 148.3% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,341 shares of the company’s stock valued at $37,000 after acquiring an additional 801 shares in the last quarter. Institutional investors own 75.33% of the company’s stock.

More Moderna News

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: FDA staff said Moderna’s flu vaccine data may support effectiveness in adults 65 and older, a constructive sign ahead of a key advisory meeting that could improve the odds of approval. US FDA staff says data may support effectiveness of Moderna’s flu vaccine in older adults
• Positive Sentiment: Moderna announced organizational changes, including a new chief commercial officer and an expanded role for President Stephen Hoge, signaling the company is preparing more aggressively for potential product launches in 2027 and 2028. Moderna Announces Organizational Changes to Prepare for Multiple Product Launches in 2027 and 2028
• Positive Sentiment: Market commentary noted renewed investor attention on Moderna after the FDA review and leadership updates, reinforcing optimism around the company’s late-stage vaccine pipeline. Why Moderna Is Capturing Market Attention Again?
• Neutral Sentiment: Several reports framed the move as a reaction to the FDA’s balanced review and broader speculation about a potential first mRNA flu shot, but these developments are still dependent on the upcoming advisory process. Why is Moderna (MRNA) stock soaring today?
• Negative Sentiment: FDA staff also scrutinized the evidence supporting the flu vaccine, highlighting that approval is not guaranteed and leaving some regulatory risk in place. FDA staff scrutinizes evidence supporting Moderna’s flu vaccine

Moderna Stock Performance

Shares of MRNA stock opened at $55.40 on Wednesday. The company’s fifty day simple moving average is $49.79 and its 200-day simple moving average is $44.57. The company has a quick ratio of 2.35, a current ratio of 2.41 and a debt-to-equity ratio of 0.08. Moderna, Inc. has a 12 month low of $22.28 and a 12 month high of $59.55. The firm has a market cap of $21.98 billion, a PE ratio of -6.80 and a beta of 1.05.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings results on Friday, May 1st. The company reported ($3.40) EPS for the quarter, missing the consensus estimate of ($3.02) by ($0.38). Moderna had a negative return on equity of 26.64% and a negative net margin of 143.55%.The business had revenue of $389.00 million for the quarter, compared to the consensus estimate of $236.37 million. During the same period last year, the firm earned ($2.52) earnings per share. The company’s quarterly revenue was up 260.2% compared to the same quarter last year. Equities research analysts expect that Moderna, Inc. will post -6.51 EPS for the current fiscal year.

Insider Buying and Selling at Moderna

In other Moderna news, Director Noubar Afeyan sold 9,263 shares of the business’s stock in a transaction dated Thursday, May 21st. The shares were sold at an average price of $46.84, for a total transaction of $433,878.92. Following the sale, the director directly owned 3,924 shares of the company’s stock, valued at $183,800.16. The trade was a 70.24% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, President Stephen Hoge sold 53,336 shares of the business’s stock in a transaction dated Friday, May 15th. The stock was sold at an average price of $48.40, for a total transaction of $2,581,462.40. Following the sale, the president directly owned 1,477,997 shares in the company, valued at $71,535,054.80. This trade represents a 3.48% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 71,752 shares of company stock valued at $3,453,843. Corporate insiders own 10.80% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently commented on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Moderna in a research report on Friday. The Goldman Sachs Group boosted their price objective on shares of Moderna from $43.00 to $49.00 and gave the company a “neutral” rating in a research report on Friday, May 1st. Morgan Stanley set a $33.00 price objective on shares of Moderna in a research report on Friday, May 1st. Piper Sandler boosted their price objective on shares of Moderna from $63.00 to $69.00 and gave the company an “overweight” rating in a research report on Monday, February 23rd. Finally, UBS Group reaffirmed a “neutral” rating on shares of Moderna in a research report on Tuesday, May 26th. Two equities research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and five have issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Reduce” and a consensus target price of $36.60.

About Moderna

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.